IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection

@article{Lagging2006IP10PV,
  title={IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection},
  author={Martin Lagging and Ana I. Romero and Johan Westin and Gunnar Norkrans and Amar Paul Dhillon and Jean Michel Pawlotsky and Stefan Zeuzem and Michael von Wagner and Francesco Negro and Solko W. Schalm and Bart L. Haagmans and Carlo Ferrari and Gabriele Missale and Avidan U. Neumann and Elke Verheij-Hart and Kristoffer Hellstrand},
  journal={Hepatology},
  year={2006},
  volume={44}
}
Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP‐10 levels prior to treatment with pegylated interferon‐α‐2a and ribavirin. Significantly lower IP‐10 levels were observed in patients achieving a rapid viral response (RVR) (P < .0001), even in those with body mass index (BMI) ≥ 25 kg/m2 (P = .004) and with baseline viral load ≥ 2 million IU/mL (P = .001). Similarly, significantly lower IP‐10 levels were observed in patients obtaining a sustained viral response (SVR) (P… Expand
Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
TLDR
When IL28B genotype is combined with pretreatment serum IP‐10 measurement, the predictive value for discrimination between SVR and nonresponse is significantly improved, especially in non‐CC genotypes. Expand
IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV
TLDR
Investigating the utility of baseline plasma interferon-gamma inducible protein-10 levels in human immunodeficiency virus (HIV)–hepatitis C virus (HCV) co-infected patients concluded that baseline IP-10 <150 pg/ml is predictive of a favourable viral response to HCV therapy in HIV–HCV co- infected patients, and may thus be useful in encouraging such difficult-to-treat patients to initiate therapy. Expand
Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
TLDR
In patients with chronic hepatitis C, low levels of intrahepatic and systemic IP‐10 predict a favorable first‐phase decline of HCV RNA during therapy with pegylated interferon and ribavirin for genotypes ofHCV. Expand
New Biomarkers for Response to Treatment of HCV Infected Patients Based on IP-10 and IL 28B Polymorphism Analysis
TLDR
Preliminary results have shown that pretreatment serum IP-10 level when added to IL28 genotype, the predictive value is greatly enhanced especially for CT and TT IL27 genotypes. Expand
Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms
TLDR
Concomitant assessment of pretreatment IP-10 and IL28B-related SNPs augments the prediction of the first phase decline in HCV RNA, RVR, and final therapeutic outcome. Expand
IP-10 in chronic hepatitis C patients treated with high-dose interferon.
TLDR
In patients treated with high induction dose interferon, IP-10 levels at any time point were not predictive for SVR, suggesting that, in this cohort, for prediction of SVR the added value of IP- 10 to IL28B genotype and early viral kinetics is limited. Expand
ip-10 proTein aT chronic hepaTiTis c anD iTs role in forecasTing TreaTmenT ouTcomes
Clinical values were identified for serum levels of g interferon-induced protein (IP-10) to be employed in forecasting SVR to AVT for CHC, which was carried out involving 107 patients (50 females andExpand
IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV–HCV Coinfection
TLDR
An IP-10 cutoff level of 400 pg/ml might serve as a useful predictive marker for anti- HCV therapy in HIV-HCV-coinfected patients because it could discriminate patients with expected NR or HCV relapse after therapy from patients with an SVR before starting antiviral treatment. Expand
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors
TLDR
A logistic regression model that includes the sequence of ISDR of the HCV, Th1/Th2 ratio, body weight, and neutrophil count can be useful for accurately predicting actual SVR rate before combination therapy. Expand
Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection
TLDR
High IP‐10 levels at acute HCV detection were associated with failure to spontaneously clear HCV, and patients with acuteHCV and high baseline IP‐ 10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
TLDR
Pretreatment serum IP-10 behaves as a predictive factor of SVR to peginterferon plus ribavirin therapy in genotype 1 infected patients, and is associated with different outcomes to antiviral therapy. Expand
Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.
  • P. Ferenci
  • Medicine
  • The Journal of antimicrobial chemotherapy
  • 2004
TLDR
The rapidity of viral elimination may be a useful guide to tailoring the length of treatment in patients with an EVR, and the outcome of PEG-IFN alfa-2a/RBV combination therapy is dependent on the Rapidity of the virological response. Expand
Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C
TLDR
Early confirmation of viral reduction following initiation of antiviral therapy for chronic hepatitis C is worthwhile and provides a goal to motivate adherence during the first months of therapy and a milepost at which to reassess the need for continued treatment. Expand
Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load
TLDR
The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response, and might facilitate development of rational and effective therapeutic strategies. Expand
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.
Chronic infection with the hepatitis C virus (HCV) is associated with failures of T-cell-mediated immune clearance and with abnormal B-cell growth and activation. We examined the levels of chemokinesExpand
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
TLDR
An improvement in virologic efficacy was not achieved with the available individualized treatment options and Histamine in addition to peginterferon and ribavirin and high-dose peginerferon plus Ribavirin did not improve virology response rates in patients with FPR and NUR. Expand
Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.
TLDR
It is shown that steatosis in genotype 3 infected patients is a risk factor for progression of fibrosis, and patients with genotypes 3 and steatotic ought to be recommended for early therapeutic intervention. Expand
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
TLDR
Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin. Expand
Progression of fibrosis in untreated patients with hepatitis C virus infection.
TLDR
It was found that higher age at the time of infection was associated with development of cirrhosis, that moderate intake of alcohol wasassociated with fibrosis progression, and that an inflammatory response in the form of moderate interface hepatitis in the first biopsy was not necessarily associated with greater progression of fibrosis if the second biopsy showed mild interface hepatitis. Expand
PEGINTERFERON ALFA-2 a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS
A BSTRACT Background Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat. In patients with chronic hepatitis C but without cirrhosis, once-weekly administrationExpand
...
1
2
3
...